CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570) Cancer Therapeutics (1180)
Viracta Therapeutics is a clinical-stage drug development company focused on advancing a proprietary viral activation therapy platform to address cancers associated with the Epstein-Barr Virus (EBV) and additional virus-associated diseases.
Company (IPO / Went public)
Phone: 858-400-8470
2533 S. Coast Hwy 101
Suite 210
Cardiff, 92007
California, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Viracta Therapeutics | $142.8M | Nov 30, 2020 |
| Adastra Pharmaceuticals | $90.7M | Nov 1, 2019 |
| Inimex Pharmaceuticals | $25.5M | Jun 13, 2008 |
| See all 13 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Methods of treating virally associated cancers with histone deacetylase inhibitors | Jul 08, 2020 | Mar 23, 2021 | Patent |
| Methods and compositions for treating viral or virally-induced conditions | Apr 23, 2018 | Dec 08, 2020 | Patent |
| Epigenetic modifiers for use in cellular immunotherapy | Jan 11, 2019 | Application | |
| Histone deacetylase inhibitors for use in immunotherapy | Jul 14, 2017 | Application | |
| Hdac inhibitors for use with nk cell based therapies | Jul 14, 2017 | Application |
